Taken 2008 Dual Audio 72013
Download ::: https://urlin.us/2tnEm9
The level of LDL-C may be correlated with the risk of ASCVD. Indeed, statin therapy has been shown to reduce the risk of cardiovascular events and prolong all-cause and cardiovascular mortality in individuals with clinical ASCVD. In contrast, the benefits of statin therapy in individuals without clinical ASCVD are much less clear. Statin therapy in high-risk individuals without clinical ASCVD has been associated with modest reductions in cardiovascular events and reductions in all-cause and cardiovascular mortality, but at the expense of increased adverse effects, such as myopathy. Statins have been associated with increased risk for diabetes and modestly increased risk for noncardiovascular mortality.
The public health importance of secondary prevention in patients with clinical ASCVD is reflected in the widespread use of statins for secondary prevention, as well as the high prevalence of statin use in the general population and in the primary-prevention setting. A similar logic also applies to primary prevention in those with primary elevations of LDL-C. The question is whether the potential benefits of statin therapy should be reserved for a broad group of individuals with 5% to 3d9ccd7d82
https://www.srilankanair.net/group/mysite-200-group/discussion/612164fd-88a6-4a7b-b840-be82ff78a00d
https://www.tavlinim.co.il/forum/general-discussions/gtr-evolution-patch-1201-no-cd